Management of cryptococcal meningitis in sub-saharan Africa

Current HIV/AIDS Reports

Volumn 7, Issue 3, 2010, Pages 134-142

  Jackson, Arthur ^a   Hosseinipour, Mina C ^a  

^a UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

Author keywords

AIDS; Amphotericin B; Cryptococcal antigen; Cryptococcal meningitis; Cryptococcus neoformans; Early fungicidal activity; Fluconazole; Flucytosine; HIV; Immune reconstitution inflammatory syndrome; Intracranial pressure; Lumbar puncture; Resource limited settings; Sub Saharan Africa

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; FUNGAL PROTEIN; FUNGUS ANTIGEN; ANTIFUNGAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CEREBROSPINAL FLUID PRESSURE; CLINICAL FEATURE; CLINICAL TRIAL; COLONY FORMING UNIT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC TEST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; PRIMARY PREVENTION; PROTEIN CEREBROSPINAL FLUID LEVEL; RECOMMENDED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT; AFRICA SOUTH OF THE SAHARA; COMPLICATION; DEVELOPING COUNTRY; DRUG EFFECTS; HEALTH CARE PLANNING; HIV INFECTIONS; MENINGITIS, CRYPTOCOCCAL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DEVELOPING COUNTRIES; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MENINGITIS, CRYPTOCOCCAL; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955980549     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0052-6     Document Type: Review

References (50)

1. Okongo M, Morgan D, Mayanja B, et al.: Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998, 4:698-702.
2. French N, Gray K, Watera C, et al.: Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002, 16:1031-1038.
3. Park BJ, Wannemuehler KA, Marston BJ, et al.: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530. This article highlights the devastating effect of this underappreciated disease in resource-limited areas.
4. Ellis DH, Pfeiffer TJ: Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 1990, 336:923-925.
5. Goldman DL, Khine H, Abadi J, et al.: Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001, 107:E66.
6. Davis J, Zheng WY, Glatman-Freedman A, et al.: Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J 2007, 26:549-551.
7. Scarborough M, Gordon SB, Whitty CJ, et al.: Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007, 357:2441-2450.
8. Bicanic T, Muzoora C, Brouwer AE, et al.: Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009, 49:702-709. This article validates a useful tool for assessing efficacy of anticryptococcal regimens.
9. Graybill JR, Sobel J, Saag M, et al.: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000, 30:47-54.
10. van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15-21.
11. Maher D, Mwandumba H: Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect 1994, 28:59-64.
12. Robinson PA, Bauer M, Leal MA, et al.: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82-92.
13. Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of merica. Clin Infect is 2010, 50:291-322.
14. Bicanic T, Meintjes G, Wood R, et al.: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76-80. This article supports the use of AmB when possible for CM andhighlights the fact that lower doses of fluconazole are very ineffective at clearing disease.
15. Mwaba P, Mwansa J, Chintu C, et al.: Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001, 77:769-773.
16. Bicanic T, Harrison T, Niepieklo A, et al.: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006, 43:1069-1073.
17. Bicanic T, Wood R, Meintjes G, et al.: High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47:123-130.
18. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-1767.
19. Nussbaum JC, Jackson A, Namarika D, et al.: Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338-344. This article shows the most effective combination of oral therapies for CM to date, with EFA of fluconazole 1200 mg/day plus flucytosine approaching that of AmB alone. It lends weight to the call for flucytosine to be made available in resource-limited settings.
20. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O: Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007, 4:e21.
21. Milefchik E, Leal MA, Haubrich R, et al.: Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008, 46:393-395. This article supports the use of high-dose fluconazole with flucytosine.
22. Longley N, Muzoora C, Taseera K, et al.: Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008, 47:1556-1561. This article demonstrates the safety and efficacy of higher doses of fluconazole.
23. Pappas PG, Chetchotisakd P, Larsen RA, et al.: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48:1775-1783. This study shows improved efficacy of AmB combined with fluconazole 800 mg over AmB alone.
24. Sloan D, Dlamini S, Paul N, Dedicoat M: Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev 2008, 4:CD005647.
25. Apseloff G, Hilligoss DM, Gardner MJ, et al.: Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991, 31:358-361.
26. Bozzette SA, Larsen RA, Chiu J, et al.: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991, 324:580-584.
27. Powderly WG, Saag MS, Cloud GA, et al.: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992, 326:793-798.
28. Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDSassociated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:291-296.
29. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al.: Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003, 36:1329-1331.
30. Aberg JA, Price RW, Heeren DM, Bredt B: A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002, 185:1179-1782.
31. Bicanic T, Brouwer AE, Meintjes G, et al.: Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009, 23:701-706.
32. Loyse A, Wainwright H, Jarvis JN, et al.: Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010, 24:405-410.
33. Manosuthi W, Sungkanuparph S, Chottanapund S, et al.: Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS 2008, 19:268-271.
34. Park MK, Hospenthal DR, Bennett JE: Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999, 28:629-633.
35. Newton PN, Thai le H, Tip NQ, et al.: A randomized, doubleblind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002, 35:769-772.
36. Bisson GP, Nthobatsong R, Thakur R, et al.: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008, 49:227-229.
37. Zolopa A, Andersen J, Powderly W, et al.: Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.PLoS One 2009, 4:e5575.
38. Makadzange A, Ndhlovu CE, Takarinda K, et al.: Early vs delayed initation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010, 50:1532-1538.
39. McCarthy K, Meintjes G: Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. Southern African J HIV Med 2007, 25-35.
40. Wakeham K, Parkes-Ratanshi R, Watson V, et al.: Coadministration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010, 65:316-319.
41. Manosuthi W, Athichathanabadi C, Uttayamakul S, et al.: Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007, 7:14.
42. Bicanic T, Meintjes G, Rebe K, et al.: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009, 51:130-134.
43. Lortholary O, Fontanet A, Memain N, et al.: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS 2005, 19:1043-1049.
44. Powderly WG, Finkelstein D, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995, 332:700-705.
45. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE: A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002, 34:277-284.
46. Essential Prevention and Care Interventions for Adults and Adolescents Living With HIV in Resource-Limited Settings.World Health Organization; 2008.
47. Parkes-Ratanshi R, Kamali A, Wakeham K, et al.: Successful primary prevention of cryptococcal meningitis using fluconazole prophylaxis in HIV-infected Ugandan adults [abstract]. Conference on Retroviruses and Opportunistic Infections. 2009, In press.
48. Liechty CA, Solberg P, Were W, et al.: Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007, 12:929-935.
49. Jarvis JN, Lawn SD, Vogt M, et al.: Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862. This study suggests an approach to reduce the incidence of clincial CM in resource-limited settings by screening for CrAg in at-risk individuals.
50. Meya DB, Castelnuovo B, Kambugu A, et al.: Serum cryptococcal antigen (CRAG) screening: Cost-effective method to prevent death in HIV-infected persons with CD4 ≤100/μL in sub-Saharan Africa. Cape Town, South Africa: International AIDS Society; 2009. This study shows the cost-benefit implications of a CrAg screening approach in resource-limited settings. It is shown to be a cost-effective method.